Investigational drug · Phase 2
BIO101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Muscle Wasting, Obesity & Overweight, Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BIO101"
First trial start
2026
Jul 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BIO101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Muscle Wasting
- Obesity & Overweight
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BIO101" as an intervention, largest first.
- Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 PatientsPivotal-lookingTerminated
BiophytisIndustry
NCT04472728 · 238 participants · Start Aug 26, 2020 · Primary completion Jun 6, 2022
Drug: BIO101; Placebo · For: Covid-19; SARS-CoV2
Sites: Phoenix, Arizona; Irvine, California; Natchitoches, Louisiana · 22 sites in all
- A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)Pivotal-lookingCompleted
BiophytisIndustry
NCT03452488 · 233 participants · Start Feb 7, 2017 · Primary completion Apr 26, 2020
Drug: BIO101; Placebo · For: Sarcopenia; Gait Disorders in Old Age; Muscle Weakness
Sites: Banning, California; Garden Grove, California; San Diego, California · 22 sites in all
- Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.Pivotal-lookingNot yet recruiting
BiophytisIndustry
NCT07411378 · 164 participants (planned) · Start Jul 2026 · Primary completion Jun 2027
Drug: BIO101; Semaglutide · For: Muscle Wasting; Obesity & Overweight; Obesity
Newest research
PubMed records naming it or its code names, newest first.
- Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.
Bézier C, Cottin S, Hashemi PN, et al. · J Cachexia Sarcopenia Muscle 2025
- Neuroprotective Effect of Mas Activation by BIO101 in Vincristine-Induced Small Fiber Neuropathy.
Frachet S, Danigo A, Latil M, et al. · J Peripher Nerv Syst 2025
- BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.
Fielding RA, Dao MM, Cannon K, et al. · J Cachexia Sarcopenia Muscle 2025
- Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Lobo SM, Plantefève G, Nair G, et al. · EClinicalMedicine 2024
- The Current Landscape of Pharmacotherapies for Sarcopenia.
Bahat G, Ozkok S · Drugs Aging 2024
- BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice.
Serova M, Didry-Barca B, Deloux R, et al. · J Cachexia Sarcopenia Muscle 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.